Insys Therapeutics Inc(NASDAQ:INSY) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 3, 2016. Company reported revenue of $67.12M. Analysts estimated a revenue of $66.97M. Earnings per share were $0.13. Analysts had estimated an EPS of $0.07.
Insys Therapeutics Inc (INSY) shares turned negative on Fridays trading session with the shares closing down -0.17 points or -0.92% at a volume of 8,12,077. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $18.8. The peak price level was also seen at $18.8 while the days lowest was $18.18. Finally the shares closed at $18.37. The 52-week high of the shares is $37.31 while the 52-week low is $11.45. According to the latest information available, the market cap of the company is $1,315 M.
Several Insider Transactions has been reported to the SEC. On Jun 6, 2016, Theodore H Stanley (director) sold 16,000 shares at $16.27 per share price.Also, On May 12, 2016, John N Kapoor (CEO) purchased 50,000 shares at $12.68 per share price.On Mar 7, 2016, Patrick Fourteau (director) sold 15,000 shares at $18.22 per share price, according to the Form-4 filing with the securities and exchange commission.
Insys Therapeutics Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule a generic equivalent to Marinol (dronabinol) an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. The Companys lead product candidate is Dronabinol oral solution an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.